With a year-over-year growth in debt of 1,165.71%, Collegium Pharmaceutical Inc's debt growth rate surpasses 98.34% of about US stocks.
Over the past twelve months, COLL has reported earnings growth of -573.72%, putting it ahead of only 3.47% of US stocks in our set.
Collegium Pharmaceutical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -45.29%, greater than the shareholder yield of just 8.02% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Collegium Pharmaceutical Inc, a group of peers worth examining would be WMS, UFI, HSKA, IMAX, and AMG.
Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.
Collegium Pharmaceutical, Inc. (COLL) Q2 2020 Earnings Conference Call August 05, 2020, 16:30 ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - President, CEO & Director Paul Brannelly - EVP & CFO Scott Dreyer - EVP & Chief Commercial Officer Conference Call Participants David Steinberg - Jefferies Gregory...
Collegium Pharmaceuticals (COLL) has been a stock which intrigued me for quite a while, although I lack conviction on the thesis and a cautious bullish thesis has not played out exactly as planned yet. In February of this year, when COVID-19 was not yet in the spotlights, I concluded that...
The Value Investor on Seeking Alpha | July 20, 2020